Spinal cord injury patients who started a CGRP inhibitor, one of the migraine shots approved a few years ago, were less likely to be put on a gabapentinoid soon after than patients started on two older drugs. It is a hint, drawn from insurance-style records, that a headache medicine might reach the nerve pain that follows paralysis.
The numbers come from a study published online July 7 in the American Journal of Physical Medicine and Rehabilitation ↗. The authors queried TriNetX, a research network that pools de-identified electronic health records from health systems worldwide. They looked at adults with spinal cord injury or disorder who were started on one of three preventive agents: a CGRP inhibitor, topiramate, or propranolol. Then they asked a simple downstream question. In the 30 days after that start, did the patient also get a prescription for a gabapentinoid?
Why the gabapentinoid is the tell
Gabapentinoids are gabapentin and pregabalin, the two pills that anchor almost every treatment plan for neuropathic pain. They are also sedating, frequently ineffective, and increasingly scrutinized for misuse. In this study a new gabapentinoid script is a proxy: it flags a patient whose pain was not controlled by the first drug and who needed to escalate. Fewer gabapentinoid starts means, roughly, fewer patients who had to reach for the next thing.
Against propranolol, a blood-pressure drug also used for migraine prevention, CGRP inhibitors were associated with 25 percent lower odds of a gabapentinoid prescription (odds ratio 0.75, 95 percent confidence interval 0.62 to 0.91, from 3,527 patients). Against topiramate, an anti-seizure drug used the same way, the gap was wider: 38 percent lower odds (odds ratio 0.62, 0.53 to 0.73, from 4,890 patients). The two older drugs barely separated from each other (odds ratio 0.87, a difference small enough that the confidence interval nearly touched no effect).
Rank them and the order is clean. Patients started on topiramate reached for a gabapentinoid most often. Propranolol sat in the middle. The CGRP inhibitor group reached for one least.
The mechanism the authors are chasing
There is a real reason to look here rather than a fishing expedition. CGRP, calcitonin gene-related peptide, is a signaling molecule packed into the small pain-sensing nerve fibers that carry hurt toward the spinal cord. Those are the C-fibers and A-delta afferents. After a cord injury, they sprout abnormally in the dorsal horn, the spinal relay station, and that overgrowth is thought to help lock in chronic pain. CGRP inhibitors were built to mop up this peptide for migraine. If the same peptide is driving injury pain, blocking it could plausibly do double duty. Peptidemodel hosts the alpha-CGRP card ↗ for the natural peptide these antibodies neutralize, and the CALCR/RAMP target page ↗ for the receptor it acts through.
What this is not
This is an association, not a trial, and the outcome is a prescription pattern, not a measured drop in pain. TriNetX studies match on recorded traits. But the reasons a clinician picks a CGRP inhibitor over topiramate for a paralyzed patient are not all in the record, and those unmeasured reasons could push the result. Nobody here was randomized, and nobody's pain score was tracked.
Still, the signal is coherent with the biology and pointed in one direction across two separate comparisons. CGRP inhibitors are expensive antibodies, and spinal cord injury pain is one of the hardest problems in rehabilitation medicine, with few good options. A finding that a migraine drug might blunt it is worth a real trial. The authors say as much, and this data is the argument for running one.